Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

By I. Reid, Jacques P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J. Devogelaer, J. Kaufman, P. Jaeger and 18 more. New England Journal of Medicine, 2002

895 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/eb2caa76b0caa67950ca6468dcd8dd05de4b6624

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Orthopedics and Sports Medicine

Citations in the corpus

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, background): “With alendronate [89], suppression for a year has been observed after IV dosing, as has been observed with zoledronate [161, 95].”
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. (2003, background): “This latter bisphosphonate, in one randomized trial, reversed osteoporosis BMD with a 4 mg intravenous annual infusion.(46) After the ORAG report was released, teriparitide,(37) a synthetic parathyroid hormone, was approved for osteoporosis therapy.”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “Based on the result of a phase II study [223], a large phase III trial in over 7700 postmenopausal osteoporotic patients assessed the efficacy of yearly infusion of zoledronic acid Osteoporos Int (2019) 30:3–44 21”
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. (2006, background): “These data appear to be in marked contrast to zoledronate which displays a sustained inhibition of resorption for at least a year after a single intravenous dose of 4 mg [14].”
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws (2006, background): “The doses for oncologic indications are often up to 12 times higher than those used for osteoporosis (13, 59).”
Bisphosphonates: the first 40 years. (2011, background): “The availability of yearly intravenous treatment with zoledronate [217,218] as an effective treatment has the attraction of delivering a defined dose”